Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Disease of the Month: Cervical Cancer
Disease of the Month: Cervical Cancer
“Get Informed, Get Screened, Get Vaccinated” – WHO Introduction: Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…
January 12, 2023
J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)
J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)
Shots:  Roche was the top dealmaker in 2022 with a completion of 31 deals with multiple pharma, biotech companies, and universities for a total deal value of $13.55B  The highest deal was secured by Roche under its development and commercialization collaboration with Poseida for the R&D of multiple existing and novel cell therapies for the…
January 5, 2023
Insights+ Key Biosimilars Events of December 2022
Insights+ Key Biosimilars Events of December 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Alvotech and STADA launched Hukyndra (biosimilar, adalimumab)…
January 4, 2023
PharmaShots' Most Read News of 2022
PharmaShots’ Most Read News of 2022
The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022 1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…
January 2, 2023
PharmaShots' Key Highlights of Fourth Quarter 2022
PharmaShots’ Key Highlights of Fourth Quarter 2022
Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…
December 29, 2022
Insights+ EMA Marketing Authorization of New Drugs in November 2022
Insights+: EMA Marketing Authorization of New Drugs in November 2022
Shots: The EMA approved 4 New Chemical Entity (NCE) and 4 Biologic Drugs in November 2022, leading to treatments for patients and advances in the healthcare industry In November 2022, the major highlights drugs were Skyrizi's approval for active crohn's disease, Beyfortus for RSV lower respiratory tract disease PharmaShots has compiled a list of a…
December 28, 2022
Top Performing Drug of 2021 – Opdivo (December Edition)
Top Performing Drug of 2021 – Opdivo (December Edition)
Active Ingredient: Nivolumab  Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial  Dosage Form: Injection  Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1)  First Approval: US (22 Dec 2014), EU (19 Jun 2015)   Revenue Analysis of Opdivo BMS’ Opdivo gives tough competition to other drugs in the…
December 22, 2022
Disease of the Month: AIDS
Disease of the Month: AIDS
“Putting Ourselves to the Test: Achieving Equity to End HIV”  -Theme of the year 2022  Introduction: HIV/AIDS is one of the top 10 cause of mortality. It is a chronic, epidemic disease caused by human immunodeficiency virus (HIV), a virus that infect WBC’s CD4 T-cell of the immune system. HIV, a type of retrovirus that isn't…
December 20, 2022
Insights+ The US FDA New Drug Approvals in November 2022
Insights+: The US FDA New Drug Approvals in November 2022
The US FDA approved 1 NDAs and 6 BLA in November 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 73 novel products in 2022 In November 2022, the major highlights drugs were Imfinzi (durvalumab) + Imjudo (tremelimumab) approval for metastatic non-small cell lung cancer, Elahere for…
December 15, 2022
Load more